AAAAAA
Results: 1-25/44
Authors:
UGWUMADU AHN
CARMICHAEL PL
NEVEN P
Citation: Ahn. Ugwumadu et al., TAMOXIFEN AND THE FEMALE GENITAL-TRACT, International journal of gynecological cancer, 8(1), 1998, pp. 6-15
Authors:
NEVEN P
VERGOTE I
Citation: P. Neven et I. Vergote, CONTROVERSIES REGARDING TAMOXIFEN AND UTERINE CARCINOMA, Current opinion in obstetrics & gynecology, 10(1), 1998, pp. 9-14
Authors:
VERGOTE I
NEVEN P
VANDERICK G
VANDAM P
VANBELLE Y
DESUTTER P
DEPRINS F
DEMUYLDER X
CLAERHOUT J
CAMPO R
ALBERTYN G
Citation: I. Vergote et al., TAMOXIFEN AND THE UTERUS, European journal of cancer, 34, 1998, pp. 1-3
Authors:
NEVEN P
DEMUYLDER X
VANBELLE Y
CAMPO R
VANDERICK G
Citation: P. Neven et al., FROM THE BREAST TO THE UTERUS - THE PAST AND THE PRESENT, European journal of cancer, 34, 1998, pp. 8-9
Authors:
CARMICHAEL PL
MILLS JJ
NEVEN P
Citation: Pl. Carmichael et al., AN EPIGENETIC MECHANISM FOR TAMOXIFEN-ASSOCIATED UTERINE CARCINOGENESIS, European journal of cancer, 34, 1998, pp. 10-11
Authors:
DEMUYLDER X
NEVEN P
VANBELLE Y
Citation: X. Demuylder et al., TAMOXIFEN AND BENIGN ENDOMETRIAL LESIONS, European journal of cancer, 34, 1998, pp. 18-19
Authors:
VANBELLE Y
CAMPO R
NEVEN P
DEMUYLDER X
VANDERICK G
Citation: Y. Vanbelle et al., TAMOXIFEN AND THE UTERUS - THE HYSTEROSCOPIC APPROACH, European journal of cancer, 34, 1998, pp. 31-32
Authors:
VANHOE L
GRYSPEERDT S
BLOEMEN H
TIMMERMAN D
NEVEN P
MARCHAL G
VERGOTE I
Citation: L. Vanhoe et al., TAMOXIFEN-INDUCED CHANGES OF THE UTERUS - MRI FEATURES, European journal of cancer, 34, 1998, pp. 36-37
Authors:
CARMICHAEL PL
NEVEN P
SARDAR S
VANHOOF I
UGWUMADU A
BOURNE T
TOMAS E
HELLBERG P
HEWER A
DAVIS W
PHILLIPS DH
Citation: Pl. Carmichael et al., A LACK OF EVIDENCE FOR THE GENOTOXICITY OF TAMOXIFEN AND TOREMIFENE IN THE HUMAN ENDOMETRIUM, European journal of cancer, 34, 1998, pp. 106-106
Authors:
NEVEN P
MESTDAGH C
VANHOOFF I
MOERMAN P
Citation: P. Neven et al., ENDOMETRIAL CHANGES DURING TAMOXIFEN TREATMENT - REPLY, Lancet, 351(9105), 1998, pp. 838-838
Authors:
NEVEN P
VERGOTE I
Citation: P. Neven et I. Vergote, SHOULD TAMOXIFEN USERS BE SCREENED FOR ENDOMETRIAL LESIONS, Lancet, 351(9097), 1998, pp. 155-157
Authors:
NEVEN P
DEMUYLDER X
VANBELLE Y
VANHOOFF I
VANDERICK G
Citation: P. Neven et al., LONGITUDINAL HYSTEROSCOPIC FOLLOW-UP DURING TAMOXIFEN TREATMENT, Lancet, 351(9095), 1998, pp. 36-36
Authors:
DALCIN P
TIMMERMAN D
VANDENBERGHE I
WANSCHURA S
KAZMIERCZAK B
VERGOTE I
DEPREST J
NEVEN P
MOERMAN P
BULLERDIEK J
VANDENBERGHE H
Citation: P. Dalcin et al., GENOMIC CHANGES IN ENDOMETRIAL POLYPS ASSOCIATED WITH TAMOXIFEN SHOW NO EVIDENCE FOR ITS ACTION AS AN EXTERNAL CARCINOGEN, Cancer research, 58(11), 1998, pp. 2278-2281
Authors:
NEVEN P
Citation: P. Neven, ANY QUESTIONS - HOW LONG IS IT SAFE TO TAKE TAMOXIFEN, BMJ. British medical journal, 315(7099), 1997, pp. 36-36
Authors:
PIROTTE B
DETULLIO P
NEVEN P
DEWALQUE D
DELARGE J
CAIGNARD DH
RENARD P
Citation: B. Pirotte et al., THE CHEMISTRY OF THALIMIDOMETHYL-4H-PYRIDO[4,3-E]-1,2,4-THIADIAZINE 1,1-DIOXIDES AND THEIR USE IN THE SYNTHESIS OF POTENTIAL CHOLECYSTOKININ GASTRIN RECEPTORS LIGANDS/, Bulletin des Societes chimiques belges, 106(12), 1997, pp. 781-790
Authors:
NEVEN P
DEMUYLDER X
VANBELLE Y
Citation: P. Neven et al., TAMOXIFEN-INDUCED ENDOMETRIAL POLYP, The New England journal of medicine, 336(19), 1997, pp. 1389-1389
Authors:
DETULLIO P
PIROTTE B
NEVEN P
MASEREEL B
DEWALQUE D
DIOUF O
PODONA T
CAIGNARD D
RENARD P
DELARGE J
Citation: P. Detullio et al., SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW 3-ARALKYLAMINO-2-ARYL-2H-1,2,4-PYRIDOTHIADIAZINE 1,1-DIOXIDES AS POTENTIAL CCK-RECEPTOR LIGANDS, Journal of Pharmacy and Pharmacology, 49(5), 1997, pp. 463-471
Authors:
PIEL G
PIROTTE B
DELNEUVILLE I
NEVEN P
LLABRES G
DELARGE J
DELATTRE L
Citation: G. Piel et al., STUDY OF THE INFLUENCE OF BOTH CYCLODEXTRINS AND L-LYSINE ON THE AQUEOUS SOLUBILITY OF NIMESULIDE - ISOLATION AND CHARACTERIZATION OF NIMESULIDE-L-LYSINE-CYCLODEXTRIN COMPLEXES, Journal of pharmaceutical sciences, 86(4), 1997, pp. 475-480
Authors:
NEVEN P
Citation: P. Neven, TAMOXIFEN - THE NEED FOR A MONITORING PROTOCOL, Breast, 5(4), 1996, pp. 330-331
Authors:
ASSIKIS VJ
NEVEN P
JORDAN VC
VERGOTE I
Citation: Vj. Assikis et al., A REALISTIC CLINICAL PERSPECTIVE OF TAMOXIFEN AND ENDOMETRIAL CARCINOGENESIS, European journal of cancer, 32A(9), 1996, pp. 1464-1476
Authors:
BUNTINX F
NEVEN P
Citation: F. Buntinx et P. Neven, WHICH QUESTIONNAIRE TO MEASURE PSYCHOSOCIAL EFFECTS OF HAVING AN ABNORMAL PAP SMEAR, Journal of clinical epidemiology, 49(12), 1996, pp. 1469-1469
Authors:
MEUNIER F
KAUSHIK SC
NEVEN P
POYELLE F
Citation: F. Meunier et al., A COMPARATIVE THERMODYNAMIC STUDY OF SORPTION SYSTEMS - 2ND LAW ANALYSIS, International journal of refrigeration, 19(6), 1996, pp. 414-421
Authors:
CARMICHAEL PL
UGWUMADU AHN
NEVEN P
HEWER AJ
POON GK
PHILLIPS DH
Citation: Pl. Carmichael et al., LACK OF GENOTOXICITY OF TAMOXIFEN IN HUMAN ENDOMETRIUM, Cancer research, 56(7), 1996, pp. 1475-1479
Authors:
NEVEN P
DEMUYLDER X
Citation: P. Neven et X. Demuylder, HORMONAL INTERVENTIONS AND CANCER RISK, Lancet, 346, 1995, pp. 8-8
Authors:
NEVEN P
Citation: P. Neven, ENDOMETRIAL CHANGES IN PATIENTS ON TAMOXIFEN, Lancet, 346(8985), 1995, pp. 1292-1292